Stéphane Dorich

This inventor holds 14 USPTO granted patents and 16 published patent applications and 1 EPO patent. Top assignees: Ventus Therapeutics U.s., Inc., Repare Therapeutics Inc.. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stéphane Dorich. Retrieved from https://idiyas.com/inventor/stéphane-dorich

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 16)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 12)

Average Co-Inventor Count = 1.7

ph-index = 3

Forward Citations = 31(Granted Patents)

Company Filing History:

12 out of 13

Ventus Therapeutics U.s., Inc.

patents

2 out of 3

Repare Therapeutics Inc.

patents

Years Active: 2022-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12662481 - Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors (2026-06-23),

2. 12441728 - Pyridazine compounds for inhibiting NLRP3 (2025-10-14),

3. 12410167 - Pyridazine compounds for inhibiting NLRP3 (2025-09-09),

4. 12398136 - Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors (2025-08-26),

5. 12351578 - Compounds for inhibiting NLRP3 and uses thereof (2025-07-08),

6. 12331048 - Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors (2025-06-17),

7. 12312351 - Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors (2025-05-27),

8. 12312350 - Compounds for inhibiting NLRP3 and uses thereof (2025-05-27),

9. 12281112 - Compounds for inhibiting NLRP3 and uses thereof (2025-04-21),

10. 12264155 - Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors (2025-04-01),

11. 12195460 - Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors (2025-01-14),

12. 12168657 - Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives (2024-12-17),

13. 11618751 - Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives (2023-04-04),

14. 11319319 - Compounds for inhibiting NLRP3 and uses thereof (2022-05-03),

Title: Stéphane Dorich: Innovator in Pyridazine Compounds

Introduction

Stéphane Dorich is a notable inventor based in Pointe-Claire, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific proteins involved in various diseases. With a total of 13 patents to his name, Dorich's work is recognized for its potential impact on medical treatments.

Latest Patents

One of Stéphane Dorich's latest patents involves pyridazine compounds designed for inhibiting NLRP3. This patent outlines the use of inhibitors of NLRP3, which are useful in treating diseases and disorders associated with this protein. The formula presented in the patent showcases the innovative approach Dorich has taken in addressing complex health issues.

Career Highlights

Throughout his career, Stéphane Dorich has worked with several prominent companies in the biotechnology sector. Notably, he has been associated with Ventus Therapeutics U.S., Inc. and Repare Therapeutics Inc. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research.

Collaborations

Stéphane Dorich has collaborated with talented individuals in his field, including Stéphane Ciblat and Amandine Chefson. These partnerships have fostered an environment of innovation and creativity, leading to advancements in their shared research interests.

Conclusion

Stéphane Dorich is a distinguished inventor whose work in pyridazine compounds has the potential to revolutionize treatments for various diseases. His contributions to the field, along with his collaborations, highlight the importance of innovation in medical research.

Profile summary based on public USPTO records.